Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.30 |
| ▸ | MAOB | P27338 | 4/20 | 0.30 |
| ▸ | MAOA | P21397 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19342868 | 0.75 | PIM1 (0.41) | PIM1SIGMAR1 | |
| SCHEMBL24388705 | 0.75 | CYP3A4 (0.32) | TSHR | |
| SCHEMBL4959690 | 0.69 | CFTR (0.32) | — | |
| SCHEMBL63455 | 0.67 | CHRM2 (0.40) | CHRM2CHRM4CHRM1CHRM3SIGMAR1 | |
| SCHEMBL6129709 | 0.67 | CHRM2 (0.40) | CHRM2CHRM4CHRM1CHRM3SIGMAR1 | |
| SCHEMBL27890860 | 0.67 | CHRM2 (0.37) | TSHRCHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL4795914 | 0.66 | SIGMAR1 (0.31) | SIGMAR1 | |
| SCHEMBL14851373 | 0.65 | CFTR (0.32) | PIM1MAOBMAOA | |
| SCHEMBL7108506 | 0.64 | CHRM2 (0.49) | TSHRCHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL3971547 | 0.64 | CHRM2 (0.49) | TSHRCHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11710854-B2 | Functional epoxides in catalyst-based electrolyte compositions for Li-ion batteries | ENEVATE CORPORATION (US) | 2023-07-25 | — | — | US | claimed |
| US-20220140392-A1 | FUNCTIONAL EPOXIDES IN CATALYST-BASED ELECTROLYTE COMPOSITIONS FOR LI-ION BATTERIES | ENEVATE CORPORATION | 2022-05-05 | — | — | US | claimed |
| WO-2022093797-A1 | FUNCTIONAL EPOXIDES IN CATALYST-BASED ELECTROLYTE COMPOSITIONS FOR LI-ION BATTERIES | ENEVATE CORPORATION (US) | 2022-05-05 | — | — | WO | claimed |
| US-11710854-B2 | Functional epoxides in catalyst-based electrolyte compositions for Li-ion batteries | ENEVATE CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| US-11710854-B2 | Functional epoxides in catalyst-based electrolyte compositions for Li-ion batteries | ENEVATE CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| US-11710854-B2 | Functional epoxides in catalyst-based electrolyte compositions for Li-ion batteries | ENEVATE CORPORATION (US) | 2023-07-25 | — | — | US | disclosed |
| US-20220140392-A1 | FUNCTIONAL EPOXIDES IN CATALYST-BASED ELECTROLYTE COMPOSITIONS FOR LI-ION BATTERIES | ENEVATE CORPORATION | 2022-05-05 | — | — | US | disclosed |
| WO-2022093797-A1 | FUNCTIONAL EPOXIDES IN CATALYST-BASED ELECTROLYTE COMPOSITIONS FOR LI-ION BATTERIES | ENEVATE CORPORATION (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20220140392-A1 | FUNCTIONAL EPOXIDES IN CATALYST-BASED ELECTROLYTE COMPOSITIONS FOR LI-ION BATTERIES | ENEVATE CORPORATION | 2022-05-05 | — | — | US | disclosed |
| US-9765064-B1 | Alpha-hydroxy-beta-azido-tetrazoles | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-09-19 | — | — | US | disclosed |
| US-9765064-B1 | Alpha-hydroxy-beta-azido-tetrazoles | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-09-19 | — | — | US | disclosed |
| CN-1251991-A | Carboxylic acid derivatives, their preparation and their use in cancer therapy | BASF AG (DE) | 2000-05-03 | — | — | CN | disclosed |
| US-6030975-A | ANTAGONIST OF ENDOTHELINS, I.E. INHIBITION OF BINDING WITH RECEPTOR; ANTITUMOR AND -CARCINOGENIC AGENTS; SIDE EFFECT REDUCTION | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-29 | — | — | US | disclosed |
| EP-0969841-A1 | USE OF CARBOXYLIC ACID DERIVATIVES FOR TREATING CANCER | BASF AKTIENGESELLSCHAFT (DE) | 2000-01-12 | — | — | EP | disclosed |
| US-5969134-A | CARDIOVASCULAR DISORDERS, VASOCONSTRICTION, HYPOTENSIVE AGENTS AND RELEASE OF ENDOTHELINS | BASF AKTIENGESELLSCHAFT (DE) | 1999-10-19 | — | — | US | disclosed |
| US-5932730-A | Carboxylic acid derivatives, their preparation and use | BASF AKTIENGESELLSCHAFT (DE) | 1999-08-03 | — | — | US | disclosed |
| WO-1998041206-A1 | NOVEL CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE IN TREATING CANCER | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-24 | — | — | WO | disclosed |
| EP-0785926-A1 | NEW CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1997-07-30 | — | — | EP | disclosed |
| WO-1996011914-A1 | NEW CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1996-04-25 | — | — | WO | disclosed |
| US-3975431-A | Preparing carboxylic acids from glycidonitriles through enol acylates | THE UPJOHN COMPANY (US) | 1976-08-17 | — | — | US | disclosed |